Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Systemic Treatment.
- Author:
Jung Eun KIM
1
;
Hyun Jeong KIM
;
Bark Lynn LEW
;
Kyung Ho LEE
;
Seung Phil HONG
;
Yong Hyun JANG
;
Kui Young PARK
;
Seong Jun SEO
;
Jung Min BAE
;
Eung Ho CHOI
;
Ki Beom SUHR
;
Seung Chul LEE
;
Hyun Chang KO
;
Young Lip PARK
;
Sang Wook SON
;
Young Jun SEO
;
Yang Won LEE
;
Sang Hyun CHO
;
Chun Wook PARK
;
Joo Young ROH
Author Information
- Publication Type:Original Article
- Keywords: Administration; oral; Dermatitis; Guideline; Korea; Therapeutics
- MeSH: Consensus*; Cyclosporine; Dermatitis; Dermatitis, Atopic*; Histamine Antagonists; Humans; Hypersensitivity; Immunologic Factors; Immunotherapy; Korea*; Phototherapy; Pruritus; Quality of Life
- From:Annals of Dermatology 2015;27(5):578-592
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were issued by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been further advances in the systemic treatment of AD. OBJECTIVE: We aimed to establish updated evidence- and experience-based systemic treatment guidelines for Korean AD. METHODS: We compiled a database of references from relevant systematic reviews and guidelines regarding the systemic management of AD, including antihistamines, antimicrobials, systemic immunomodulators, allergen-specific immunotherapy, phototherapy, adjunctive treatment, and complementary and alternative medicines. Evidence for each statement was graded and classified based on the strength of the recommendation. Thirty-nine council members of KADA participated in the three rounds of votes and expert consensus recommendations were established. RESULTS: The use of antihistamines is recommended to relieve pruritus and to prevent exacerbation due to scratching in AD patients. Infection should be controlled as needed and long-term medication should be avoided. For moderate to severe AD patients, concomitant active treatments with systemic immunomodulators are indicated. Cyclosporine is the first choice among systemic immunomodulators and others should be considered as second-line alternatives. Allergen-specific immunotherapy could be effective in AD patients with aeroallergen hypersensitivity. Phototherapy can be useful for moderate to severe AD patients and narrow-band ultraviolet B is the most effective option. Complementary and alternative medicines cannot be recommended for treating AD. CONCLUSION: We expect these recommendations to be a reference guide for physicians and AD patients in choosing the appropriate treatment to improve quality of life and decrease unnecessary social medical costs.
